CSL Behring is a global biotherapeutics leader driven by its promise to save lives. We develop and deliver innovative therapies to improve patients' life. Our portfolio includes a wide range of recombinant and plasma-derived products. In Switzerland, CSL Behring has a manufacturing site in Bern.
Products, services, technology
Biotherapies treating rare diseases such as von Willebrand disease (VWD), hemophilia, primary immunodeficiency (PID), hereditary angioedema (HAE), Alpha-1 antitrypsin deficiency, and biotherapies to prevent hemolytic disease of the newborn, and prevent/stop bleeding in emergencies/planned surgery.
Our partnering approach is to structure deals that leverage the value of our R&D, commercial and manufacturing operations. We partner with industry leaders, academia, governments and scientific organizations to contribute our know-how and technologies to bring innovative medicines to life.